Published in TB and Outbreaks Week, August 17th, 2004
The patent grants exclusive rights to Bavarian Nordic upon issuance (of U.S. Patent 6,761,893) and claims MVA-BN and derivatives thereof.
Safety in humans continues to be the overriding challenge in vaccine development and production. The USPTO's patent grant to the MVA-BN virus, which is nonreplicative in humans, acknowledges the novelty and utility of such a virus exhibiting the demonstrated excellent safety profile of the MVA-BN technology and other claimed MVA viruses exhibiting similar...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.